New 7-[4-(4-(un)Substituted)piperazine-1-carbonyl]-piperazin-1-yl] Derivatives of Fluoroquinolone: Synthesis and Antimicrobial Evaluation

Fluoroquinolones have been a class of important synthetic antimicrobial agents broadly and effectively used in clinic for infectious diseases. In this study, the synthesis of a range of fluoroquinolone derivatives with 4-(carbopiperazin-1-yl)piperazinyl moieties at the C7 position and their inhibition of bacterial pathogens commonly disseminated in hospital environment were described. The results indicated that a 7-[4-(4-(benzoyl)carbopiperazin-1-yl)]piperazinyl derivative 5h and two 7-[4-(4-(benzenesulfonyl)carbopiperazin-1-yl)]piperazinyl derivatives 5k and 5l showed more promising growth inhibition of ciprofloxacin-resistant P. aeruginosa (CRPA) with MIC values as low as 16 μg/mL which is 16-fold more potent than ciprofloxacin, while most of other derivatives maintained potency against methicillin-resistant Staphylococcus aureus (MRSA).

[1]  J. Karlowsky,et al.  Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. , 2013, The Journal of antimicrobial chemotherapy.

[2]  Xingshu Li,et al.  4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: novel C7 moieties of fluoroquinolones as antibacterial agents. , 2010, Bioorganic & medicinal chemistry letters.

[3]  L. Garcia Tests to Assess Bactericidal Activity , 2010 .

[4]  C. Biot,et al.  Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. , 2009, Journal of medicinal chemistry.

[5]  P. Yogeeswari,et al.  Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. , 2006, Bioorganic & medicinal chemistry letters.

[6]  E. Goldstein,et al.  Fluoroquinolones and anaerobes. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Yogeeswari,et al.  Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. , 2005, Bioorganic & medicinal chemistry.

[8]  A. V. Shindikar,et al.  Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. , 2005, Bioorganic & medicinal chemistry letters.

[9]  L. Mitscher Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. , 2005, Chemical reviews.

[10]  V. Jarlier,et al.  Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity , 2004, Antimicrobial Agents and Chemotherapy.

[11]  K. Hino,et al.  Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1. , 2002, Journal of medicinal chemistry.

[12]  T. Gootz,et al.  Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects , 1996, Medicinal research reviews.

[13]  R. R. Bower,et al.  In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria. , 1986, The Journal of antimicrobial chemotherapy.